25 October 2016
Teva back where Vigodman started
Since becoming CEO, Erez Vigodman has seen Teva's share price climb 40%, and slide all the way down again, but the sell-off may have been overdone.
FDA accepts Teva new drug resubmission
The US Food and Drug Administration has accepted the resubmission of the New Drug Application for SD-809 for the treatment of chorea associated with Huntington disease.